Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Neuroblastoma or Cancer
and you are
between 1 and 21
years old
This is an early phase trial to determine
the dosage and safety of the new treatment.
Show me locations

The purpose

The purpose of this research study is to match genomic aberrations in tumor cells at time of relapse to rationally designed combinations of molecularly targeted agents. This study will be done in two parts: Part I: Tumor will be accessed at study entry via a biopsy and subjected to deep sequencing to identify protocol-specified biomarkers for therapy assignment. Part II: If the tumor contains a genetic change defined by the study as being actionable, and other criteria are met, participants will be assigned to therapy based upon the genetic changes identified in the tumor biopsy.

Provided treatments

  • Procedure: Biopsy
  • Drug: Ceritinib
  • Drug: Trametinib
  • Drug: HDM201
  • Genetic: Next Generation Sequencing
  • Procedure: Tumor Scans
  • Radiation: X-ray
  • Procedure: Bone marrow Tests
  • Other: Physical Exam
  • Other: Eye Exam
  • Other: Labs
  • Other: Pregnancy Test
  • Behavioral: Interviews
  • Other: ECG
  • Other: Echocardiogram
  • Drug: Ribociclib
Wondering what is the locations section for?
We will connect you to the doctor responsible for this trial and help you get more information.

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT02780128. The sponsor of the trial is Yael P Mosse and it is looking for 105 volunteers for the current phase.
Official trial title:
Next Generation Personalized Neuroblastoma Therapy (The NEPENTHE Trial)